Interferon-α Therapy following Autologous Peripheral Blood Stem Cell Transplantation for Adult T Cell Leukemia/Lymphoma

Fujiwara, Hiroshi; Arima, Naomichi; Akasaki, Yuichi; Ohtsubo, Hideo; Ozaki, Atsuo; Kukita, Toshimasa; Matsushita, Kakushi; Arimura, Kosei; Suruga, Yukio; Wakamatsu, Shinichi; Matsumoto, Tadashi; Hidaka, Shiroh; Eizuru, Yoshito

doi:10.1159/000058317

Cited by 13 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…241 In general, these stimulatory soluble factors have largely been used to augment antitumor responses in the context of MRD following autologous HSCT. [242][243][244] Not surprisingly, clinical experience with their use in the allogeneic setting has been disappointing, largely due to their potential to enhance deleterious alloreactivity in the transplant recipient. 245 Inactivation or attenuation of effector cell function.…”

Section: Soluble Factors and Their Targetsmentioning

confidence: 99%

Immune restoration following hematopoietic stem cell transplantation: an evolving target

Auletta

Lazarus

2005

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Hematopoietic stem cell transplantation (HSCT) is the definitive cure for many malignant and nonmalignant diseases. However, delays in immune reconstitution (IR) following HSCT significantly limit the success of transplantation and increase the risk for infection and disease relapse in the transplant recipient. Therefore, ways to measure and to manipulate immune recovery following HSCT are emerging and their success depends directly upon an enhanced understanding for the underlying mechanisms responsible for reconstituted immunity and hematopoiesis. Recent discoveries in the activation, function, and regulation of dendritic cell (DC), natural killer (NK) cell, and T-lymphocyte subtypes have been critical in developing immunotherapies used to prevent graft-versushost disease and to enhance graft-versus-leukemia. For example, regulatory T cells that induce tolerance and NK receptor-tumor ligand disparities that result in tumor lysis are being used to minimize GVHD and tumor burden, respectively. Furthermore, expansion and modulation of immune effector cells are being used to augment hematopoietic and immune recovery and to decrease transplantrelated toxicity in the transplant recipient. Specifically, DC expansion and incorporation into antitumor and antimicrobial vaccines is fast approaching application into clinical trials. This paper will review our current understanding for IR following HSCT and the novel ways in which to restore immune function and decrease transplantrelated toxicity in the transplant recipient. Bone Marrow Transplantation (2005) 35, 835-857.

show abstract

Section: Soluble Factors and Their Targetsmentioning

confidence: 99%

Immune restoration following hematopoietic stem cell transplantation: an evolving target

Auletta

Lazarus

2005

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…27 Autologous transplant has all but been abandoned in ATLL given the poor results. 33-36 There is a general consensus that those with advanced stage or relapsed/refractory NK/TCL should undergo a consolidative transplant, the type of transplant is less apparent especially in the SMILE era. 30 In HSTCL, consolidative stem cell transplant appears to have an important role as almost all long-term survivors have undergone transplantation.…”

Section: Treatment Optionsmentioning

confidence: 99%

Treatment of Peripheral T-cell Lymphoma: Are We Data Driven or Driving the Data?

Lunning

Horwitz

2013

Curr. Treat. Options in Oncol.

View full text Add to dashboard Cite

Opinion Statement Peripheral T-cell lymphomas (PTCL) are a group of uncommon and heterogeneous malignancies arising from a post-thymic or mature T-lymphocyte. The treatment of PTCL remains a challenging endeavor. Compared to the more common aggressive B-cell lymphomas, more patients with PTCL will be refractory to initial therapy and those who achieve responses will often have shorter progression free survival. Despite retrospective data suggesting that anthracycline based multi-agent chemotherapy regimens may not provide a benefit compared to non-anthracycline regimens, non-anthracycline based regimens, with the notable exception of L-asparaginase regimens for extranodal NK/T-cell lymphoma, have been disappointing so far. Based on phase II evidence and subset analyses available, we believe that the addition of etoposide to standard regimens and consolidation of first remissions with autologous stem cell transplantation (autoSCT) provides the best outcome in patients with PTCL and currently use CHOEP followed by ASCT for eligible patients with the common PTCL subtype: PTCL-NOS, AITL, and ALK negative ALCL. For those with ALK positive ALCL standard CHOP or CHOEP is appropriate with consideration of ASCT only for those with high-risk disease. Other strategies to incorporate additional agents such as with dose adjusted-EPOCH or sequential CHOP-ICE regimens are logical options; however, they lack the supporting literature of CHOEP. While the above recommendation is our current off-protocol approach, with the possible exception of low risk ALK positive ALCL, none of these choices is supported by strong enough data to supplant a well-conceived clinical trial as the truly preferred strategy in PTCL. The novel agents, romidepsin, pralatrexate and brentuximab vedotin, are currently approved in the relapsed/refractory setting. These agents are being studied as additions or substitutions for other agents in up-front multi-agent chemotherapy regimens. In the relapsed/refractory setting both pralatrexate and romidepsin remain well-studied choices with some patients achieving a response with durability. Clinical trials of new agents in PTCL continue to be a valuable option and an important part of routine patient management as progressive disease is often seen. Lastly, we believe patients with relapsed/refractory PTCL should be considered for allogeneic stem cell transplantation if a suitable response is demonstrated and a willing donor is available.

show abstract

“…Notably, cutaneous ATLL lesions seem to be more sensitive to interferon than other lesions (51, 53, 57, 59, 60). The mechanism of anti‐ATLL activity in vivo with no significant activities in vitro might be explained by immunomodulation such as an increase in interferon‐γ and/or tumor necrosis factor (TNF)‐α secreted by CD3 and CD8 double‐positive T cells in the peripheral blood or in tissues stimulated by exogenous interferon (58). Although reports indicate a modest decrease in HTLV‐I provirus load in CD4 + lymphocytes and mononuclear cells derived from patients with HAM/TSP treated with interferon‐α in vitro or in vivo (61–63), this study has not been duplicated in ATLL patients.…”

Section: Interferonmentioning

confidence: 99%

Treatment of adult T‐cell leukemia/lymphoma: past, present, and future

Ishitsuka

Tamura

2007

European J of Haematology

View full text Add to dashboard Cite

Adult T‐cell leukemia/lymphoma (ATLL) is a peripheral T‐cell malignancy caused by human T‐cell lymphotrophic virus type I. Clinical manifestations of ATLL range from smoldering to chronic, lymphoma and acute. Patients with acute and lymphoma type ATLL require therapeutic intervention. Conventional chemotherapeutic regimens used against other malignant lymphoma have been administered to ATLL patients, but the therapeutic outcomes of acute and lymphoma type ATLL remain very poor. Promising results of allogeneic stem cell transplantation (SCT) for ATLL patients have recently been reported and the treatment outcome might be improved for some ATLL patients. Besides conventional chemotherapy and SCT, interferon, zidovudine, arsenic trioxide, targeted therapy against surface molecule on ATLL cells, retinoid derivatives, and bortezomib have been administered to ATLL patients in pilot or phase I/II studies. Further studies are required to confirm the clinical benefits of these novel therapeutics. This article reviews the current status and future directions of ATLL treatment.

show abstract

Interferon-α Therapy following Autologous Peripheral Blood Stem Cell Transplantation for Adult T Cell Leukemia/Lymphoma

Cited by 13 publications

References 20 publications

Immune restoration following hematopoietic stem cell transplantation: an evolving target

Immune restoration following hematopoietic stem cell transplantation: an evolving target

Treatment of Peripheral T-cell Lymphoma: Are We Data Driven or Driving the Data?

Treatment of adult T‐cell leukemia/lymphoma: past, present, and future

Contact Info

Product

Resources

About